Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Can plixorafenib redefine thyroid cancer treatment? Inside FORE Biotherapeutics’ latest trial results FORE Biotherapeutics reveals ATA 2025 data showing plixorafenib’s long-lasting effects in BRAF-altered thyroid cancers. See why it’s generating investor buzz. byPallavi MadhirajuSeptember 13, 2025